Use of hepadnavirus core proteins as vaccine platforms

References

• Peters B, Sidney J, Bourne P et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol.3(3), e91 (2005).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40(1), 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Clarke BE, Newton SE, Carroll AR et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature330(6146), 381–384 (1987).
   PubMed Web of Science ®Google Scholar
• Howard CR. The biology of hepadnaviruses. J. Gen. Virol.67(Pt 7), 1215–1235 (1986).
   PubMed Web of Science ®Google Scholar
• Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev.64(1), 51–68 (2000).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Gerety RJ, Barker LF. Antibody to hepatitis-B-virus core in man. Lancet2(7834), 869–873 (1973).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature329(6139), 547–549 (1987).
   PubMed Web of Science ®Google Scholar
• Bottcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature386(6620), 88–91 (1997).
   PubMed Web of Science ®Google Scholar
• Conway JF, Cheng N, Zlotnick A, Wingfield PT, Stahl SJ, Steven AC. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature386(6620), 91–94 (1997).
   PubMed Web of Science ®Google Scholar
• Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol. Cell3(6), 771–780 (1999).
   PubMed Web of Science ®Google Scholar
• Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol.63(2), 798–808 (1989).
   PubMed Web of Science ®Google Scholar
• Schodel F, Moriarty AM, Peterson DL et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol.66(1), 106–114 (1992).
   PubMed Web of Science ®Google Scholar
• Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J. Virol.64(7), 3319–3330 (1990).
   PubMed Web of Science ®Google Scholar
• Watts NR, Conway JF, Cheng N et al. The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO J.21(5), 876–884 (2002).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Lee BO et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine25(9), 1593–1606 (2007).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Schodel F et al. Comparative antigenicity and immunogenicity of hepadnavirus core proteins. J. Virol.79(21), 13641–13655 (2005).
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine20(3–4), 370–376 (2001).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Barr M et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol.79(21), 13656–13666 (2005).
   PubMed Web of Science ®Google Scholar
• Walker A, Skamel C, Vorreiter J, Nassal M. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. J. Biol. Chem.283(48), 33508–33515 (2008).
   PubMed Web of Science ®Google Scholar
• Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl Acad. Sci. USA83(6), 1578–1582 (1986).
   PubMed Web of Science ®Google Scholar
• Ziermann R, Ganem D. Homologous and heterologous complementation of HBV and WHV capsid and polymerase functions in RNA encapsidation. Virology219(2), 350–356 (1996).
   PubMed Web of Science ®Google Scholar
• Huang Z, Santi L, LePore K, Kilbourne J, Arntzen CJ, Mason HS. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine24(14), 2506–2513 (2006).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Stahl S et al. Comparative immunogenicity of hepatitis B virus core and E antigens. J. Immunol.141(10), 3617–3624 (1988).
   PubMed Web of Science ®Google Scholar
• Zheng J, Schodel F, Peterson DL. The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern. J. Biol. Chem.267(13), 9422–9429 (1992).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot A, Lechner F et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine20(25–26), 3104–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J. Immunol.32(11), 3305–3314 (2002).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol.172(9), 5598–5605 (2004).
   PubMed Web of Science ®Google Scholar
• Fu TM, Grimm KM, Citron MP et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine27(9), 1440–1447 (2009).
   PubMed Web of Science ®Google Scholar
• Beesley KM, Francis MJ, Clarke BE et al. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties. Biotechnology (NY)8(7), 644–649 (1990).
   PubMedGoogle Scholar
• Borisova GP, Berzins I, Pushko PM et al. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett.259(1), 121–124 (1989).
   PubMed Web of Science ®Google Scholar
• Brown AL, Francis MJ, Hastings GZ et al. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine9(8), 595–601 (1991).
   PubMed Web of Science ®Google Scholar
• Clarke BE, Brown AL, Grace KG et al. Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria. J. Gen. Virol.71(Pt 5), 1109–1117 (1990).
   PubMed Web of Science ®Google Scholar
• Francis MJ, Hastings GZ, Brown AL et al. Immunological properties of hepatitis B core antigen fusion proteins. Proc. Natl Acad. Sci. USA87(7), 2545–2549 (1990).
   PubMed Web of Science ®Google Scholar
• Moriarty A, McGee JS, Winslow B et al. Expression of HIV gag and env B-cell epitopes on the surface of HBV core particles and analysis of the immune responses generated to those epitopes. In: Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Press, NY, USA, 225 (1990).
   Google Scholar
• Schodel F, Milich DR, Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol.145(12), 4317–4321 (1990).
   PubMed Web of Science ®Google Scholar
• Stahl SJ, Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl Acad. Sci. USA86(16), 6283–6287 (1989).
   PubMed Web of Science ®Google Scholar
• von Brunn A, Brand M, Reichhuber C, Morys-Wortmann C, Deinhardt F, Schodel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine11(8), 817–824 (1993).
   PubMed Web of Science ®Google Scholar
• Karpenko LI, Ivanisenko VA, Pika IA et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids18(4), 329–337 (2000).
   PubMed Web of Science ®Google Scholar
• Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA96(5), 1915–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Skamel C, Ploss M, Bottcher B et al. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J. Biol. Chem.281(25), 17474–17481 (2006).
   PubMed Web of Science ®Google Scholar
• Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J. Immunol.35(2), 655–665 (2005).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med.94(6), 744–748 (1981).
   PubMed Web of Science ®Google Scholar
• Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J. Clin. Invest.91(6), 2586–2595 (1993).
   PubMed Web of Science ®Google Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol.13, 29–60 (1995).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Moriarty A, Thornton GB. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J. Immunol.139(4), 1223–1231 (1987).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science234(4782), 1398–1401 (1986).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science262(5138), 1448–1451 (1993).
   PubMed Web of Science ®Google Scholar
• Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl Acad. Sci. USA94(26), 14648–14653 (1997).
   PubMed Web of Science ®Google Scholar
• Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl Acad. Sci. USA95(16), 9477–9481 (1998).
   PubMed Web of Science ®Google Scholar
• Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J. Immunol.175(5), 3165–3176 (2005).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate. J. Gen. Virol.86(Pt 1), 75–84 (2005).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Serruys B, Leroux-Roels G. Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator. J. Virol.81(5), 2535–2536 (2007).
   PubMed Web of Science ®Google Scholar
• Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G. Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. J. Gen. Virol.86(Pt 2), 323–331 (2005).
   PubMed Web of Science ®Google Scholar
• Lee BO, Tucker A, Frelin L et al. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol.182(11), 6670–6681 (2009).
   PubMed Web of Science ®Google Scholar
• Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity28(6), 799–809 (2008).
   PubMed Web of Science ®Google Scholar
• Schodel F, Wirtz R, Peterson D et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med.180(3), 1037–1046 (1994).
   PubMed Web of Science ®Google Scholar
• Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology44(2–3), 98–114 (2001).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature328(6127), 257–259 (1987).
   PubMed Web of Science ®Google Scholar
• Zavala F, Tam JP, Hollingdale MR et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science228(4706), 1436–1440 (1985).
   PubMed Web of Science ®Google Scholar
• Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science207(4426), 71–73 (1980).
   PubMed Web of Science ®Google Scholar
• Zavala F, Tam JP, Barr PJ et al. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med.166(5), 1591–1596 (1987).
   PubMed Web of Science ®Google Scholar
• Schodel F, Peterson D, Milich DR, Charoenvit Y, Sadoff J, Wirtz R. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge. Behring Inst. Mitt. (98), 114–119 (1997).
   PubMedGoogle Scholar
• Milich DR, Hughes J, Jones J, Sallberg M, Phillips TR. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate. Vaccine20(5–6), 771–788 (2001).
   PubMed Web of Science ®Google Scholar
• Birkett A, Lyons K, Schmidt A et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun.70(12), 6860–6870 (2002).
   PubMed Web of Science ®Google Scholar
• Langermans JA, Schmidt A, Vervenne RA et al. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria vaccine ICC-1132 in macaques. Vaccine23(41), 4935–4943 (2005).
   PubMed Web of Science ®Google Scholar
• Gregson AL, Oliveira G, Othoro C et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One3(2), e1556 (2008).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun.72(11), 6519–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine23(7), 857–864 (2005).
   PubMed Web of Science ®Google Scholar
• Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol.65(10), 5491–5498 (1991).
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Lamb RA. Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucleic Acids Res.17(7), 2870 (1989).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• De Filette M, Min Jou W, Birkett A et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology337(1), 149–161 (2005).
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu. Rev. Pharmacol. Toxicol.49, 303–326 (2009).
   PubMed Web of Science ®Google Scholar
• Ionescu RM, Przysiecki CT, Liang X et al. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci.95(1), 70–79 (2006).
   PubMed Web of Science ®Google Scholar
• Murata Y, Lightfoote PM, Rose RC, Walsh EE. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol. J.6, 81 (2009).
   PubMedGoogle Scholar
• Kumar S, Ochoa W, Singh P et al. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology388(1), 185–190 (2009).
   PubMed Web of Science ®Google Scholar
• Denis J, Acosta-Ramirez E, Zhao Y et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine26(27–28), 3395–3403 (2008).
   PubMed Web of Science ®Google Scholar